AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Can… (NCT07285694) | Clinical Trial Compass
RecruitingPhase 1/2
AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)
United States190 participantsStarted 2026-01-09
Plain-language summary
This is a multi-center, open-label Phase 1/2 trial evaluating the safety and efficacy of AB-3028 in subjects with metastatic castration resistant prostate cancer (mCRPC).
Who can participate
Age range
18 Years
Sex
MALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. At least 18 years of age at time of signing informed consent form.
. Histologically confirmed adenocarcinoma of the prostate, meeting all of the following criteria:
. Prior prostate cancer treatment with at least 1 novel androgen receptor pathway inhibitor (ARPI) therapy.
. Adequate organ functions.
Exclusion criteria
. Any prior systemic therapy for CRPC within 14 days prior to scheduled protocol required leukapheresis.
. Central nervous system (CNS) metastatic disease, leptomeningeal disease, or cord compression.
. Unwillingness to participate in an extended safety monitoring period.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Since AB-3028 is a brand-new type of therapy called a 'programmable circuit T cell,' can you explain what that means in simple terms and how it's different from other T cell or CAR-T therapies I might have heard about?
2This is a Phase 1/2 trial where the main goal is figuring out whether AB-3028 is safe and tolerable — not yet proving it works — so what does that mean for my personal risk compared to sticking with standard treatments for mCRPC?
3Given that this trial is still in its early phases and safety data is still being collected, what known or expected side effects should I be aware of before deciding whether to discuss enrolling?
4How would participating in this trial affect my day-to-day life — for example, how often would I need to come in for treatment or monitoring, and are there any restrictions on other medications I'm currently taking for my prostate cancer?
5Before considering this trial, are there standard-of-care options for metastatic castration-resistant prostate cancer that I haven't tried yet that might be worth pursuing first?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Safety and tolerability of AB-3028
Timeframe: From AB-3028 infusion up to 24 months post-infusion